Publicaciones en colaboración con investigadores/as de Mayo Clinic (28)

2024

  1. Human Leukocyte Antigen Signatures as Pathophysiological Discriminants of Microscopic Colitis Subtypes

    Journal of Crohn's and Colitis, Vol. 18, Núm. 3, pp. 349-359

2022

  1. Genetics, pathobiology and therapeutic opportunities of polycystic liver disease

    Nature Reviews Gastroenterology and Hepatology, Vol. 19, Núm. 9, pp. 585-604

2021

  1. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders

    Nature Genetics, Vol. 53, Núm. 11, pp. 1543-1552

  2. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models

    Journal of Hepatology, Vol. 74, Núm. 2, pp. 394-406

2020

  1. Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets

    Liver International, Vol. 40, Núm. 7, pp. 1670-1685

2018

  1. Faecal microbiota composition associates with abdominal pain in the general population

    Gut

  2. Female-Specific Association Between Variants on Chromosome 9 and Self-Reported Diagnosis of Irritable Bowel Syndrome

    Gastroenterology, Vol. 155, Núm. 1, pp. 168-179

  3. Increased Prevalence of Rare Sucrase-isomaltase Pathogenic Variants in Irritable Bowel Syndrome Patients

    Clinical Gastroenterology and Hepatology

  4. MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

    Hepatology, Vol. 67, Núm. 4, pp. 1420-1440

2017

  1. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma

    Journal of Hepatology, Vol. 67, Núm. 1, pp. 72-83

  2. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma

    Hepatology, Vol. 66, Núm. 4, pp. 1125-1143

  3. TRPM8 polymorphisms associated with increased risk of IBS-C and IBS-M

    Gut, Vol. 66, Núm. 9, pp. 1725-1727

2016

  1. Immunotherapy in colorectal cancer: What have we learned so far?

    Clinica Chimica Acta, Vol. 460, pp. 78-87

2015

  1. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease

    Journal of Hepatology, Vol. 63, Núm. 4, pp. 952-961

2014

  1. Clinical relevance of KRAS mutations in codon 13: Where are we?

    Cancer Letters

  2. Corrigendum to Clinical relevance of KRAS mutations in codon 13: Where are we? [Cancer Lett. 343 (1 (2013) 1-5]

    Cancer Letters

  3. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases

    Gut, Vol. 63, Núm. 10, pp. 1658-1667

2013

  1. Alcohol consumption on pancreatic diseases

    World Journal of Gastroenterology, Vol. 19, Núm. 5, pp. 638-647

  2. Epigenetic regulation of autophagy by the methyltransferase G9a

    Molecular and Cellular Biology, Vol. 33, Núm. 20, pp. 3983-3993

  3. Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation

    Journal of Biological Chemistry, Vol. 288, Núm. 17, pp. 11786-11794